Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352
Recruiting
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system. However, more information is needed on the ways in which the cells of the immune system interact with the central nervous system (CNS). This study will compare tests performed on both healthy volunteers and individuals who have signs or symptoms of immune-related damage to their CNS. This study will include two groups of subjects at least... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
05/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Central Nervous System Disease, Multiple Sclerosis
Register for Updates
Screening Volunteers for Clinical Trials
NCT01375530
Recruiting
Background: - The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health needs healthy volunteers for vaccine clinical trials. This is a screening study that is used to identify healthy volunteers who may be eligible to participate in other clinical trials at the Vaccine Research Center that evaluate investigational vaccines, monoclonal antibodies, and injection devices. The VRC conducts studies that will allow researchers to better understand the imm... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/15/2025
Locations: Emory University, Atlanta, Georgia +3 locations
Conditions: Screening
Register for Updates
Characterization of Diseases With Salivary Gland Involvement
NCT02327884
Recruiting
Background: - Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life. Studying people who have a disease that affects their salivary gland(s) may teach researchers about the disorders and their genetics. Objectives: - To study salivary gland diseases and disorders. To collect data and samples from people with salivary gland problems and their relatives. Eligibility: * People more than 4 years old who have or are suspect... Read More
Gender:
ALL
Ages:
Between 4 years and 100 years
Trial Updated:
05/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer, Salivary Gland Disease, Sjogren's Syndrome
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005
Recruiting
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study: Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: City of Hope, Duarte, California +38 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767
Recruiting
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Kingman Regional Medical Center, Kingman, Arizona +251 locations
Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Register for Updates
Neonatal Phase 1 Valacyclovir Study
NCT05468619
Recruiting
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration.... Read More
Gender:
ALL
Ages:
Between 1 day and 2 days
Trial Updated:
05/15/2025
Locations: Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama +11 locations
Conditions: Herpes Simplex
Register for Updates
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588
Recruiting
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: UCLA Hematology/Oncology - Santa Monica ( Site 0023), Los Angeles, California +183 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
NCT06337708
Recruiting
The purpose of this study is to test a culturally tailored, smartphone-delivered intervention designed to increase physical activity and reduce risk for heart disease and type 2 diabetes among African American women.
Gender:
FEMALE
Ages:
Between 24 years and 65 years
Trial Updated:
05/15/2025
Locations: Arizona State University, Phoenix, Arizona
Conditions: Physical Activity, Exercise, Heart Diseases, Diabetes Mellitus, Physical Inactivity
Register for Updates
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
NCT06551506
Recruiting
Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause of mortality in children \<5 years of age worldwide. Until recently, no Food and Drug Administration (FDA)-approved vaccines were available to prevent RSV infection. The only prophylactic product for RSV prevention recommended for infants was the monoclonal antibody palivizumab, but administration was limited to those with extreme prematur... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
05/15/2025
Locations: Emory University School of Medicine, Atlanta, Georgia +7 locations
Conditions: Respiratory Syncytial Virus Infection
Register for Updates
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT06686394
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey +5 locations
Conditions: Breast Neoplasms, Breast Cancer
Register for Updates
Home-Based tDCS Treatment Of Major Depressive Disorder
NCT06976697
Recruiting
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
05/15/2025
Locations: Lindus Health virtual site, New York, New York
Conditions: Major Depressive Disorder (MDD)
Register for Updates
Study of Premenstrual Syndrome and Premenstrual Dysphoria
NCT00001177
Recruiting
The purpose of this study is to identify and describe the symptoms of premenstrual syndrome (PMS). Women who experience PMS symptoms will complete clinical interviews, self-rating scales, and evaluations of mood and endocrine function. A subgroup of women with severe PMS (Premenstrual Dysphoric Disorder or PMDD) will be offered additional research studies that focus on: 1) identifying the endocrine changes that may be responsible for changes in mood and behavior during the premenstrual period,... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mood Disorder
Register for Updates